КРАТКИЙ ОБЗОР КЛИНИЧЕСКИХ ИСПЫТАНИЙ СРЕДСТВ ИММУНОТЕРАПИИ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ

В течение последнего десятилетия был достигнут большой прогресс в понимании биологии рака и его взаимодействия с иммунной системой. В клинической практике для лечения онкологических заболеваний широко применяются иммунотерапевтические препараты на основе рекомбинантных цитокинов и моноклональных антител, разработано большое количество экспериментальных способов лечения онкологических заболеваний, многие из которых в данный момент проходят различные стадии клинических испытаний. Одобрение рекомбинантного онколитического герпесвируса T-VEC для лечения меланомы стало очередным важным шагом на пути к созданию эффективных и безопасных противораковых препаратов. В данном обзоре мы рассмотрим некоторые наиболее перспективные стратегии иммунотерапии онкологических заболеваний: ингибиторы контрольных точек иммунного ответа, клеточную терапию и онколитические вирусы.

1. Максютов Р.А., Трегубчак Т.В., Денисова Н.И., Максютов А.З., Гаврилова Е.В. Создание современной платформы, содержащей набор онколитических вирусов с иммуностимулирующими свойствами // Российский иммунологический журнал, 2013. Т. 7, № 16. С. 456-459. [Maksyutov R.A., Tregubchak T.V., Denisova N.I., Maksyutov A.Z., Gavrilova E.V. Creating a modern platform comprising a set of oncolytic viruses with immunestimulating properties. Rossiyskiy immunologicheskiy zhurnal = Russian Immunological Journal, 2013, Vol. 7, no. 16, pp. 456-459. (In Russ.)]

2. Моисеенко В.М., Волков, Н.М. Важнейшие события в онкологии в 2014 году: иммунотерапия злокачественных опухолей // Практическая онкология, 2015. Т. 16, № 1. С. 6-12. [Moiseenko V.M., Volkov N.M. The most important events in the oncology in 2014: cancer immunotherapy. Prakticheskaya onkologiya = Practical Oncology, 2015, Vol. 16, no. 1, pp. 6-12. (In Russ.)]

3. Нетёсов С.В., Кочнева Г.В., Локтев В.Б., Святченко В.А., Сергеев А.Н., Терновой В.А., Тикунова Н.В., Шишкина Л.Н., Чумаков П.М. Онколитические вирусы: достижения и проблемы // Медицинский алфавит, 2011. № 3. С. 26-33. [Netesov S.V., Kochneva G.V., Loktev V.B., Sviatchenko V.A., Sergeev A.N., Ternovoi V.A. Tikunova N.V., Shishkina L.N., Chumakov P.M. Oncolytic viruses: achievements and problems. Meditsinskiy alfavit = Medical Alphabet, 2011, no. 3, pp. 26-33. (In Russ.)]

4. Румянцев А.А., Тюляндин С.А. Эффективность ингибиторов контрольных точек иммунного ответа в лечении солидных опухолей // Практическая онкология, 2016. Т. 17, № 2. С. 74-89. [Rumyantsev A.A., Tyulandin S.A. Efficacy of immune checkpoints inhibitors in the treatment of solid tumors. Prakticheskaya onkologiya = Practical Oncology, 2016, Vol. 17, no. 2, pp. 74-89. (In Russ.)]

5. Aarntzen E.H.J.G., De Vries I.J.M., Lesterhuis W.J., Schuurhuis D., Jacobs J.F.M., Bol K., Schreibelt G., Mus R., De Wilt J.H.W., Haanen J.B.A.G., Schadendorf D., Croockewit A., Blokx W.A.M., Van Rossum M.M., Kwok W.W., Adema G.J., Punt C.J.A., Figdor C.G. Targeting CD4+ T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res., 2013, Vol. 73, no. 1, pp. 19-29.

6. Alkassar M., Gartner B., Roemer K., Graesser F., Rommelaere J., Kaestner L., Haeckel I., Graf N. The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo. J. Neurooncol., 2011, Vol. 104, no. 3, pp. 715-727.

7. Andtbacka R.H.I., Kaufman H.L., Collichio F., Amatruda T., Senzer N., Chesney J., Delman K.A., Spitler L.E., Puzanov I., Agarwala S.S., Milhem M., Cranmer L., Curti B., Lewis K., Ross M., Guthrie T., Linette G.P., Daniels G.A., Harrington K., Middleton M.R., Miller W.H., Zager J.S., Ye Y., Yao B., Li A., Doleman S., VanderWalde A., Gansert J., Coffin R.S. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol., 2015, Vol. 33, no. 25, pp. 2780-2788.

8. Antony G.K., Dudek A.Z. Interleukin 2 in cancer therapy. Curr. Med. Chem., 2010, Vol. 17, no. 29, pp. 3297- 3302.

9. Bei R., Scardino A. TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy. J. Biomed. Biotech., 2010, Vol. 2010, p. 102758.

10. Breitbach C.J., Arulanandam R., De Silva N., Thorne S.H., Patt R., Daneshmand M., Moon A., Ilkow C., Burke J., Hwang T.-H., Heo J., Cho M., Chen H., Angarita F.A., Addison C., McCart J.A., Bell J.C., Kirn D.H. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res., 2013, Vol. 73, no. 4, pp. 1265-1275.

11. Breitbach C.J., Lichty B.D., Bell J.C. Oncolytic viruses: therapeutics with an identity crisis. EBioMedicine, 2016, Vol. 9, pp. 31-36.

12. Brentjens R.J., Davila M.L., Riviere I., Park J., Wang X., Cowell L.G., Bartido S., Stefanski J., Taylor C., Olszewska M., Borquez-Ojeda O., Qu J., Wasielewska T., He Q., Bernal Y., Rijo I. V., Hedvat C., Kobos R., Curran K., Steinherz P., Jurcic J., Rosenblat T., Maslak P., Frattini M., Sadelain M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med., 2013, Vol. 5, no. 177, p. 177ra38.

13. Capasso C., Hirvinen M., Garofalo M., Romaniuk D., Kuryk L., Sarvela T., Vitale A., Antopolsky M., Magarkar A., Viitala T., Suutari T., Bunker A., Yliperttula M., Urtti A., Cerullo V. Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Oncoimmunology, 2016, Vol. 5, no. 4, p. e1105429.

14. Chiocca E.A., Rabkin S.D. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol. Res., 2014, Vol. 2, no. 4, pp. 295-300.

15. Cinatl J.J., Michaelis M., Driever P.H., Cinatl J., Hrabeta J., Suhan T., Doerr H.W., Vogel J.-U. Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. Neoplasia, 2004, Vol. 6, no. 6, pp. 725-735.

16. Diaconu I., Cerullo V., Hirvinen M.L.M., Escutenaire S., Ugolini M., Pesonen S.K., Bramante S., Parviainen S., Kanerva A., Loskog A.S.I., Eliopoulos A.G., Pesonen S., Hemminki A. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res., 2012, Vol. 72, no. 9, pp. 2327-2338.

17. Dizon D.S., Krilov L., Cohen E., Gangadhar T., Ganz P.A., Hensing T.A., Hunger S., Krishnamurthi S.S., Lassman A.B., Markham M.J., Mayer E., Neuss M., Pal S.K., Richardson L.C., Schilsky R., Schwartz G.K., Spriggs D.R., Villalona-Calero M.A., Villani G., Masters G. Clinical Cancer Advances 2016: Annual report on progress against cancer from the American Society Of Clinical Oncology. J. Clin. Oncol., 2016, Vol. 34, no. 9, pp. 987-1011.

18. Doniņa S., Strēle I., Proboka G., Auziņš J., Alberts P., Jonsson B., Venskus D., Muceniece A. Adapted ECHO- 7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res., 2015, Vol. 25, no. 5, pp. 421-426.

19. Farkona S., Diamandis E.P., Blasutig I.M. Cancer immunotherapy: the beginning of the end of cancer? BMC Medicine, 2016, Vol. 14, pp. 73.

20. Flamand V., Sornasse T., Thielemans K., Demanet C., Leo O., Urbain J., Moser M. Vaccination with tumorantigen-pulsed dendritic cells induces in vivo resistance to a B cell lymphoma. Adv. Exp. Med. Biol., 1993, Vol. 329, pp. 611-616.

21. Freytag S.O., Stricker H., Lu M., Elshaikh M., Aref I., Pradhan D., Levin K., Kim J.H., Peabody J., Siddiqui F., Barton K., Pegg J., Zhang Y., Cheng J., Oja-Tebbe N., Bourgeois R., Gupta N., Lane Z., Rodriguez R., DeWeese T., Movsas B. Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2014, Vol. 89, no. 2, pp. 268-276.

22. Galanis E., Hartmann L.C., Cliby W.A., Long H.J., Peethambaram P.P., Barrette B.A., Kaur J.S., Haluska P.J.J., Aderca I., Zollman P.J., Sloan J.A., Keeney G., Atherton P.J., Podratz K.C., Dowdy S.C., Stanhope C.R., Wilson T.O., Federspiel M.J., Peng K.-W., Russell S.J. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res., 2010, Vol. 70, no. 3, pp. 875-882.

23. Garnett C.T., Greiner J.W., Tsang K.-Y., Kudo-Saito C., Grosenbach D.W., Chakraborty M., Gulley J.L., Arlen P.M., Schlom J., Hodge J.W. TRICOM vector based cancer vaccines. Curr. Pharm. Des., 2006, Vol. 12, no. 3, pp. 351-361.

24. Goldenberg M.M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther., 1999, Vol. 21, no. 2, pp. 309-318.

25. Gross G., Eshhar Z. Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: Counteracting Off-Tumor toxicities for safe CAR T cell therapy. Annu. Rev. Pharmacol. Toxicol., 2016, Vol. 56, pp. 59-83.

26. Gulley J.L., Arlen P.M., Tsang K.-Y., Yokokawa J., Palena C., Poole D.J., Remondo C., Cereda V., Jones J.L., Pazdur M.P., Higgins J.P., Hodge J.W., Steinberg S.M., Kotz H., Dahut W.L., Schlom J. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res., 2008, Vol. 14, no. 10, pp. 3060-3069.

27. Gulley J.L., Madan R.A., Tsang K.Y., Jochems C., Marte J.L., Farsaci B., Tucker J.A., Hodge J.W., Liewehr D.J., Steinberg S.M., Heery C.R., Schlom J. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol. Res., 2014, Vol. 2, no. 2, pp. 133-141.

28. Gyure L.A., Barfoot R., Denham S., Hall J.G. Immunity to a syngeneic sarcoma induced in rats by dendritic lymph cells exposed to the tumour either in vivo or in vitro. Br. J. Cancer, 1987, Vol. 55, no. 1, pp. 17-20.

29. Heo J., Reid T., Ruo L., Breitbach C.J., Rose S., Bloomston M., Cho M., Lim H.Y., Chung H.C., Kim C.W., Burke J., Lencioni R., Hickman T., Moon A., Lee Y.S., Kim M.K., Daneshmand M., Dubois K., Longpre L., Ngo M., Rooney C., Bell J.C., Rhee B.-G., Patt R., Hwang T.-H., Kirn D.H. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med., 2013, Vol. 19, no. 3, pp. 329-336.

30. Heron M., Tejada-Vera B. Deaths: leading causes for 2005. Natl. Vital Stat. Rep., 2009, Vol. 58, no. 8, pp. 1-97.

31. Hodi F.S., O’Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbé C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med., 2010, Vol. 363, no. 8, pp. 711-723.

32. Hoyer S., Prommersberger S., Pfeiffer I.A., Schuler-Thurner B., Schuler G., Dörrie J., Schaft N. Concurrent interaction of DCs with CD4(+) and CD8(+) T cells improves secondary CTL expansion: It takes three to tango. Eur. J. Immunol., 2014, Vol. 44, no. 12, pp. 3543-3559.

33. Iurescia S., Fioretti D., Fazio V.M., Rinaldi M. Epitope-driven DNA vaccine design employing immunoinformatics against B-cell lymphoma: a biotech’s challenge. Biotechnol. Adv., 2011, Vol. 30, no. 1, pp. 372- 383.

34. Jähnisch H., Füssel S., Kiessling A., Wehner R., Zastrow S., Bachmann M., Rieber E.P., Wirth M.P., Schmitz M. Dendritic cell-based immunotherapy for prostate cancer. Clin. Dev. Immunol., 2010, Vol. 2010, pp. 517493.

35. Jeanbart L., Swartz M.A. Engineering opportunities in cancer immunotherapy. Proc. Natl. Acad. Sci. USA, 2015, Vol. 112, no. 47, pp. 14467-14472.

36. June C.H. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest., 2007, Vol. 117, no. 6, pp. 1466-1476.

37. Kanerva A., Nokisalmi P., Diaconu I., Koski A., Cerullo V., Liikanen I., Tahtinen S., Oksanen M., Heiskanen R., Pesonen S., Joensuu T., Alanko T., Partanen K., Laasonen L., Kairemo K., Pesonen S., Kangasniemi L., Hemminki A. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin. Cancer Res., 2013, Vol. 19, no. 10, pp. 2734-2744.

38. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Ann. Rev. Immunol., 2008, Vol. 26, pp. 677-704.

39. Kirn D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene, 2000, Vol. 19, no. 56, pp. 6660-6669.

40. Kleijn A., Kloezeman J., Treffers-Westerlaken E., Fulci G., Leenstra S., Dirven C., Debets R., Lamfers M. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity. PLoS One, 2014, Vol. 9, no. 5, pp. e97495.

41. Kochenderfer J.N., Dudley M.E., Feldman S.A., Wilson W.H., Spaner D.E., Maric I., Stetler-Stevenson M., Phan G.Q., Hughes M.S., Sherry R.M., Yang J.C., Kammula U.S., Devillier L., Carpenter R., Nathan D.-A.N., Morgan R.A., Laurencot C., Rosenberg S.A. B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood, 2012, Vol. 119, no. 12, pp. 2709-2720.

42. Kuryk L., Haavisto E., Garofalo M., Capasso C., Hirvinen M., Pesonen S., Ranki T., Vassilev L., Cerullo V. Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model. Int. J. Cancer, 2016, Vol. 139, no. 8, pp. 1883-1893.

43. Lamers C.H., Sleijfer S., van Steenbergen S., van Elzakker P., van Krimpen B., Groot C., Vulto A., den Bakker M., Oosterwijk E., Debets R., Gratama J.W. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther., 2013, Vol. 21, no. 4, pp. 904-912.

44. Lamers C.H.J. Treatment of metastatic renal cell carcinoma with autologous t-lymphocytes genetically retargeted against carbonic anhydrase IX: First Clinical Experience. J. Clin. Oncol., 2006, Vol. 24, no. 13, pp. e20-e22.

45. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., Schadendorf D., Dummer R., Smylie M., Rutkowski P., Ferrucci P.F., Hill A., Wagstaff J., Carlino M.S., Haanen J.B., Maio M., Marquez-Rodas I., McArthur G.A., Ascierto P.A., Long G.V., Callahan M.K., Postow M.A., Grossmann K., Sznol M., Dreno B., Bastholt L., Yang A., Rollin L.M., Horak C., Hodi F.S., Wolchok J.D. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med., 2015, Vol. 373, no. 1, pp. 23-34.

46. Levy B., Panicalli D., Marshall J. TRICOM: enhanced vaccines as anticancer therapy. Expert Rev. Vaccines, 2004, Vol. 3, no. 4, pp. 397-402.

47. Liang M. Clinical development of oncolytic viruses in China. Curr. Pharm. Biotechnol., 2012, Vol. 13, no. 9, pp. 1852-1857.

48. Lichty B.D., Breitbach C.J., Stojdl D.F., Bell J.C. Going viral with cancer immunotherapy. Nat. Rev. Cancer., 2014, Vol. 14, no. 8, pp. 559-567.

49. Markert J.M., Razdan S.N., Kuo H.-C., Cantor A., Knoll A., Karrasch M., Nabors L.B., Markiewicz M., Agee B.S., Coleman J.M., Lakeman A.D., Palmer C.A., Parker J.N., Whitley R.J., Weichselbaum R.R., Fiveash J.B., Gillespie G.Y. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol. Ther., 2014, Vol. 22, no. 5, pp. 1048-1055.

50. Maude S.L., Frey N., Shaw P.A., Aplenc R., Barrett D.M., Bunin N.J., Chew A., Gonzalez V.E., Zheng Z., Lacey S.F., Mahnke Y.D., Melenhorst J.J., Rheingold S.R., Shen A., Teachey D.T., Levine B.L., June C.H., Porter D.L., Grupp S.A. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med., 2014, Vol. 371, no. 16, pp. 1507-1517.

51. Maude S.L., Teachey D.T., Porter D.L., Grupp S.A. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood, 2015, Vol. 125, no. 26, pp. 4017-4023.

52. McDermott D., Haanen J., Chen T.-T., Lorigan P., O’Day S. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann. Oncol., 2013, Vol. 24, no. 10, pp. 2694-2698.

53. Melief C.J.M., van Hall T., Arens R., Ossendorp F., van der Burg S.H. Therapeutic cancer vaccines. J. Clin. Invest., 2015, Vol. 125, no. 9, pp. 3401-3412.

54. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature, 2011, Vol. 480, no. 7378, pp. 480-489.

55. Metcalf D. The colony-stimulating factors and cancer. Nat. Rev. Cancer, 2010, Vol. 10, no. 6, pp. 425-434.

56. Morgan R.A., Chinnasamy N., Abate-Daga D., Gros A., Robbins P.F., Zheng Z., Dudley M.E., Feldman S.A., Yang J.C., Sherry R.M., Phan G.Q., Hughes M.S., Kammula U.S., Miller A.D., Hessman C.J., Stewart A.A., Restifo N.P., Quezado M.M., Alimchandani M., Rosenberg A.Z., Nath A., Wang T., Bielekova B., Wuest S.C., Akula N., McMahon F.J., Wilde S., Mosetter B., Schendel D.J., Laurencot C.M., Rosenberg S.A. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother., 2013, Vol. 36, no. 2, pp. 133- 151.

57. Morgan R.A., Yang J.C., Kitano M., Dudley M.E., Laurencot C.M., Rosenberg S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther., 2010, Vol. 18, no. 4, pp. 843-851.

58. Murphy G., Tjoa B., Ragde H., Kenny G., Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 1996, Vol. 29, no. 6, pp. 371-380.

59. Nazarkina Z.K., Khar’kova M.V, Antonets D.V, Morozkin E.S., Bazhan S.I., Karpenko L.I., Vlasov V.V., Ilyichev A.A., Laktionov P.P. Design of polyepitope DNA vaccine against breast carcinoma cells and analysis of its expression in dendritic cells. Bull. Exp. Biol. Med., 2016, Vol. 160, no. 4, pp. 486-490.

60. Nishio N., Diaconu I., Liu H., Cerullo V., Caruana I., Hoyos V., Bouchier-Hayes L., Savoldo B., Dotti G. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res., 2014, Vol. 74, no. 18, pp. 5195-5205.

61. Palucka K., Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity, 2013, Vol. 39, no. 1, pp. 38-48.

62. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer, 2012, Vol. 12, no. 4, pp. 252-264.

63. Parker B.S., Rautela J., Hertzog P.J. Antitumour actions of interferons: implications for cancer therapy. Nat. Rev. Cancer, 2016, Vol. 16, no. 3, pp. 131-144.

64. Parkhurst M.R., Yang J.C., Langan R.C., Dudley M.E., Nathan D.-A.N., Feldman S.A., Davis J.L., Morgan R.A., Merino M.J., Sherry R.M., Hughes M.S., Kammula U.S., Phan G.Q., Lim R.M., Wank S.A., Restifo N.P., Robbins P.F., Laurencot C.M., Rosenberg S.A. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther., 2011, Vol. 19, no. 3, pp. 620-626.

65. Pesonen S., Diaconu I., Cerullo V., Escutenaire S., Raki M., Kangasniemi L., Nokisalmi P., Dotti G., Guse K., Laasonen L., Partanen K., Karli E., Haavisto E., Oksanen M., Karioja-Kallio A., Hannuksela P., Holm S.-L., Kauppinen S., Joensuu T., Kanerva A., Hemminki A. Integrin targeted oncolytic adenoviruses Ad5- D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int. J. Cancer, 2012, Vol. 130, no. 8, pp. 1937-1947.

66. Pol J., Buqué A., Aranda F., Bloy N., Cremer I., Eggermont A., Erbs P., Fucikova J., Galon J., Limacher J.M., Preville X., Sautès-Fridman C., Spisek R., Zitvogel L., Kroemer G., Galluzzi L. Trial Watch – Oncolytic viruses and cancer therapy. OncoImmunology, 2016, Vol. 5, no. 2, e1117740.

67. Pol J.G., Zhang L., Bridle B.W., Stephenson K.B., Rességuier J., Hanson S., Chen L., Kazdhan N., Bramson J.L., Stojdl D.F., Wan Y., Lichty B.D. Maraba virus as a potent oncolytic vaccine vector. Mol. Ther., 2014, Vol. 22, no. 2, pp. 420-429.

68. Postow M.A., Chesney J., Pavlick A.C., Robert C., Grossmann K., McDermott D., Linette G.P., Meyer N., Giguere J.K., Agarwala S.S., Shaheen M., Ernstoff M.S., Minor D., Salama A.K., Taylor M., Ott P.A., Rollin L.M., Horak C., Gagnier P., Wolchok J.D., Hodi F.S. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med., 2015, Vol. 372, no. 21, pp. 2006-2017.

69. Ranki T., Joensuu T., Jäger E., Karbach J., Wahle C., Kairemo K., Alanko T., Partanen K., Turkki R., Linder N., Lundin J., Ristimäki A., Kankainen M., Hemminki A., Backman C., Dienel K., von Euler M., Haavisto E., Hakonen T., Juhila J., Jaderberg M., Priha P., Vassilev L., Vuolanto A., Pesonen S. Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8(+) T-cell response, prominent infiltration of CD8(+) lymphocytes and Th1 type polarization. Oncoimmunology, 2014, Vol. 3, no. 10, e958937.

70. Ranki T., Pesonen S., Hemminki A., Partanen K., Kairemo K., Alanko T., Lundin J., Linder N., Turkki R., Ristimaki A., Jager E., Karbach J., Wahle C., Kankainen M., Backman C., von Euler M., Haavisto E., Hakonen T., Heiskanen R., Jaderberg M., Juhila J., Priha P., Suoranta L., Vassilev L., Vuolanto A., Joensuu T. Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers. J. Immunother. Cancer, 2016, Vol. 4, p. 17.

71. Reed C.M., Cresce N.D., Mauldin I.S., Slingluff C.L., Olson W.C. Vaccination with melanoma helper peptides induces antibody responses associated with improved overall survival. Clin. Cancer Res., 2015, Vol. 21, no. 17, pp. 3879-3887.

72. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., Weber J.S., Joshua A.M., Hwu W.J., Gangadhar T.C., Patnaik A., Dronca R., Zarour H., Joseph R.W., Boasberg P., Chmielowski B., Mateus C., Postow M.A., Gergich K., Elassaiss-Schaap J., Li X.N., Iannone R., Ebbinghaus S.W., Kang S.P., Daud A. Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, 2014, Vol. 384, no. 9948, pp. 1109-1117.

73. Roulstone V., Twigger K., Zaidi S., Pencavel T., Kyula J.N., White C., McLaughlin M., Seth R., Karapanagiotou E.M., Mansfield D., Coffey M., Nuovo G., Vile R.G., Pandha H.S., Melcher A.A., Harrington K.J. Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Ther., 2013, Vol. 20, no. 5, pp. 521-528.

74. Sadelain M., Brentjens R., Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov., 2013, Vol. 3, no. 4, pp. 388-398.

75. Schreibelt G., Bol K.F., Westdorp H., Wimmers F., Aarntzen E.H.J.G., Duiveman-de Boer T., van de Rakt M.W.M.M., Scharenborg N.M., de Boer A.J., Pots J.M., Olde Nordkamp M.A.M., van Oorschot T.G.M., Tel J., Winkels G., Petry K., Blokx W.A.M., van Rossum M.M., Welzen M.E.B., Mus R.D.M., Croockewit S.A.J., Koornstra R.H.T., Jacobs J.F.M., Kelderman S., Blank C.U., Gerritsen W.R., Punt C.J.A., Figdor C.G., de Vries I.J.M. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin. Cancer Res., 2016, Vol. 22, no. 9, pp. 2155-2166.

76. Sennikov S.V., Shevchenko J.A., Kurilin V.V., Khantakova J.N., Lopatnikova J.A., Gavrilova E.V., Maksyutov R.A., Bakulina A.Y., Sidorov S.V., Khristin A.A., Maksyutov A.Z. Induction of an antitumor response using dendritic cells transfected with DNA constructs encoding the HLA-A*02:01-restricted epitopes of tumorassociated antigens in culture of mononuclear cells of breast cancer patients. Immunol. Res., 2016, Vol. 64, no. 1, pp. 171-180.

77. Sharma P., Allison J.P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell, 2015, Vol. 161, no. 2, pp. 205-214.

78. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin., 2015, Vol. 65, no. 1, pp. 5-29.

79. Skelding K.A., Barry R.D., Shafren D.R. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride. Invest. New Drugs, 2012, Vol. 30, no. 2, pp. 568-581.

80. Tagliamonte M., Petrizzo A., Tornesello M.L., Buonaguro F.M., Buonaguro L. Antigen-specific vaccines for cancer treatment. Hum. Vaccin. Immunother., 2014, Vol. 10, no. 11, pp. 3332-3346.

81. Trakatelli M., Toungouz M., Lambermont M., Heenen M., Velu T., Bruyns C. Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes. Cancer Gene Ther., 2005, Vol. 12, no. 6, pp. 552-559.

82. Triozzi P.L., Strong T. V., Bucy R.P., Allen K.O., Carlisle R.R., Moore S.E., Lobuglio A.F., Conry R.M. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum. Gene Ther., 2005, Vol. 16, no. 1, pp. 91-100.

83. Tsun A., Miao X.N., Wang C.M., Yu D.C. Oncolytic immunotherapy for treatment of cancer. Adv. Exp. Med. Biol., 2016, Vol. 909, pp. 241-283.

84. Van Tendeloo V.F., Van de Velde A., Van Driessche A., Cools N., Anguille S., Ladell K., Gostick E., Vermeulen K., Pieters K., Nijs G., Stein B., Smits E.L., Schroyens W.A., Gadisseur A.P., Vrelust I., Jorens P.G., Goossens H., de Vries I.J., Price D.A., Oji Y., Oka Y., Sugiyama H., Berneman Z.N. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl. Acad. Sci. USA, 2010, Vol. 107, no. 31, pp. 13824-13829.

85. Villalona-Calero M.A., Lam E., Otterson G.A., Zhao W., Timmons M., Subramaniam D., Hade E.M., Gill G.M., Coffey M., Selvaggi G., Bertino E., Chao B., Knopp M. V. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors. Cancer, 2016, Vol. 122, no. 6, pp. 875-883.

86. Weber J.S., Yang J.C., Atkins M.B., Disis M.L. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol., 2015, Vol. 33, no. 18, pp. 2092-2099.

87. Whisenhunt T.R.J., Rajneesh K.F., Hackney J.R., Markert J.M. Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy. Oncolytic Virotherapy, 2015, Vol. 4 pp. 33-38.

88. Wimmers F., Schreibelt G., Sköld A.E., Figdor C.G., De Vries I.J.M. Paradigm shift in dendritic cell-based immunotherapy: From in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front. Immunol., 2014, no. 5, p. 165.

89. Woller N., Gürlevik E., Fleischmann-Mundt B., Schumacher A., Knocke S., Kloos A.M., Saborowski M., Geffers R., Manns M.P., Wirth T.C., Kubicka S., Kühnel F. Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. Mol. Ther., 2015, Vol. 23, no. 10, pp. 1630-1640.

90. Yong R.L., Shinojima N., Fueyo J., Gumin J., Vecil G.G., Marini F.C., Bogler O., Andreeff M., Lang F.F. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24- RGD to human gliomas. Cancer Res., 2009, Vol. 69, no. 23, pp. 8932-8940.

91. Yoon A.-R., Hong J., Yun C.-O. A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth. Oncotarget, 2015, Vol. 6, no. 33, pp. 34875-34891.